ARGENX SE (ARGX.BR) Stock Fundamental Analysis
Europe - EBR:ARGX - NL0010832176 - Common Stock
681.6 EUR
+3.2 (+0.47%)
Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 73 industry peers in the Biotechnology industry. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ARGX suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
ARGX had a positive operating cash flow in the past year.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.84%, ARGX belongs to the top of the industry, outperforming 91.78% of the companies in the same industry.
ARGX's Return On Equity of 21.00% is amongst the best of the industry. ARGX outperforms 87.67% of its industry peers.
ARGX has a better Return On Invested Capital (5.71%) than 83.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.71% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ARGX (41.97%) is better than 91.78% of its industry peers.
ARGX has a better Operating Margin (15.30%) than 84.93% of its industry peers.
Looking at the Gross Margin, with a value of 89.40%, ARGX belongs to the top of the industry, outperforming 84.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARGX is destroying value.
Compared to 1 year ago, ARGX has more shares outstanding
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
ARGX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 28.50 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX's Altman-Z score of 28.50 is amongst the best of the industry. ARGX outperforms 97.26% of its industry peers.
The Debt to FCF ratio of ARGX is 0.14, which is an excellent value as it means it would take ARGX, only 0.14 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.14, ARGX belongs to the best of the industry, outperforming 97.26% of the companies in the same industry.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ARGX (0.01) is better than 83.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 28.5 |
ROIC/WACC0.76
WACC7.52%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Current ratio of 5.60. This is in the better half of the industry: ARGX outperforms 79.45% of its industry peers.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a better Quick ratio (5.27) than 79.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 345.45%, which is quite impressive.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 56.80%.
The Revenue has been growing by 94.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 103.72% on average per year.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 32.89% on average per year.
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARGX is valuated quite expensively with a Price/Earnings ratio of 92.61.
Compared to the rest of the industry, the Price/Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 79.45% of the companies listed in the same industry.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.86.
Based on the Price/Forward Earnings ratio of 32.29, the valuation of ARGX can be described as expensive.
Based on the Price/Forward Earnings ratio, ARGX is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
ARGX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.61 | ||
| Fwd PE | 32.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ARGX is valued a bit cheaper than 73.97% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ARGX is valued cheaper than 80.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 158.55 | ||
| EV/EBITDA | 87.95 |
4.3 Compensation for Growth
ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 166.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y278.4%
EPS Next 3Y166.67%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:ARGX (10/6/2025, 1:42:57 PM)
681.6
+3.2 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.51%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap41.71B
Analysts84.8
Price Target735.32 (7.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14%
Revenue beat(16)13
Avg Revenue beat(16)17.53%
PT rev (1m)3.74%
PT rev (3m)6.83%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)61.86%
EPS NY rev (1m)6.02%
EPS NY rev (3m)33.8%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)20.33%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)12.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.61 | ||
| Fwd PE | 32.29 | ||
| P/S | 16.04 | ||
| P/FCF | 158.55 | ||
| P/OCF | 121.23 | ||
| P/B | 8.03 | ||
| P/tB | 8.33 | ||
| EV/EBITDA | 87.95 |
EPS(TTM)7.36
EY1.08%
EPS(NY)21.11
Fwd EY3.1%
FCF(TTM)4.3
FCFY0.63%
OCF(TTM)5.62
OCFY0.82%
SpS42.48
BVpS84.88
TBVpS81.84
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.71% | ||
| ROICexc | 15.87% | ||
| ROICexgc | 17.62% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 28.5 |
F-Score5
WACC7.52%
ROIC/WACC0.76
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y117.35%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A